Molecular cytogenetics as a tool for predicting cancer prognosis with special reference to neuroblastoma tumors

ABSTRACT

Consistent cytogenetic abnormalities have been identified in a variety of human cancer cells and some of them are related to patient prognosis. Fluorescence "in situ" hybridization (FISH) is a new methodology which can be used to detect cytogenetic anormalies within interphase cells. We present several aspects of FISH methodology and its application in several examples, including trisomy 8 detection with high specificity and sensitivity in patients with myeloid leukemias; trisomy 12 detection with higher efficiency than conventional cytogenetics in patients with chronic lymphocytic leukemia; assessment of engraftment success, chimerism, and relapse in opposite sex bone marrow transplantation; and correlation of trisomy 7 with survival time in patients with prostate tumors. We discuss also some aspects of neroblastoma tumors, one of the most frequent malignant solid tumor in childhood. At diagnosis the patient's age and tumor stage are the major prognostic factors. Favorable prognosis is associated with triploid karyotype, lack of 1p abnormalities and absence of N-myc amplication, whereas unfavorable prognosis is associated with pseudodiploid or tetraploid karyotype, 1p deletion and N-myc amplication. These abnormalities can be investigated quickly and effectively in interphase cells using FISH.